/KLRS
KLRS Stock - Kalaris Therapeutics Inc
Healthcare|BiotechnologyNASDAQ
$9.13-12.38%
$1.29 (-12.38%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-67.1%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KLRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.04 – $9.22
TARGET (TP)$3.00
STOP LOSS$8.40
RISK/REWARD1:-8.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.05
52W High$12.90
52W Low$2.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-1,117,000 | $-73,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-55,256,000 | $-13,464,000 | $-14,006,000 | $-169,818,000 | $-71,309,000 |
| Net Income | $-58,769,000 | $-14,699,000 | $-15,485,000 | $-171,962,000 | $-69,784,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-11.73 | $-42.09 | $-50.62 | $-63.00 | $-59.67 |
Company Overview
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Visit WebsiteRating Distribution
Strong Buy
1
20%
Buy / Outperform
3
60%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$17
Average Target
↑ 80.7% Upside
Now
$3
Low
$17
Average
$23
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | Citizens JMP | Initiation | Mkt Outperform | $20 |
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $23 |
| July 23rd 2025 | Piper Sandler | Resumed | Neutral | $3 |
| May 7th 2025 | Leerink Partners | Initiation | Outperform | $20 |
| April 8th 2025 | William Blair | Initiation | Outperform | - |
Earnings History & Surprises
KLRSBeat Rate
50%
Last 4 quarters
Avg Surprise
-42.1%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.64
Q4 2025
EPS Surprise History
Q4 24
+71.4%
$-0.04vs$-0.14
Q2 25
-223.1%
$-2.52vs$-0.78
Q3 25
-19.6%
$-0.61vs$-0.51
Q4 25
+3.0%
$-0.64vs$-0.66
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 6, 2026 | $-0.65 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.66 | $-0.64 | +3.0% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.51 | $-0.61 | -19.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.78 | $-2.52 | -223.1% | ✗ MISS |
Q1 2025 | Mar 7, 2025 | — | — | — | — |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.04 | +71.4% | ✓ BEAT |
Latest News
Kalaris Therapeutics Data From Phase 1a Single Dose Study Of TH103 Demonstrates Showed Mean 10-letter Gain In Visual Acuity, Rapid; TH103 Was Generally Well Tolerated
📈 PositiveBenzinga•Dec 17, 2025, 09:03 PM•Also:
Kalaris Therapeutics Q3 EPS $(0.64) Beats $(0.65) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 01:14 PM
Citizens Initiates Coverage On Kalaris Therapeutics with Market Outperform Rating, Announces Price Target of $20
📈 PositiveBenzinga•Nov 3, 2025, 02:05 PM
Kalaris Therapeutics Appoints Matthew Gall As New CFO To Support Growth And Clinical Expansion
📈 PositiveBenzinga•Nov 3, 2025, 12:38 PM
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study Of TH103 In Patients With Neovascular Age-Related Macular Degeneration.
📈 PositiveBenzinga•Sep 15, 2025, 12:09 PM
Raymond James Initiates Coverage On Kalaris Therapeutics with Strong Buy Rating, Announces Price Target of $23
📈 PositiveBenzinga•Sep 3, 2025, 04:47 PM
Kalaris Therapeutics Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Sep 3, 2025, 03:20 PM
Kalaris Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Sep 3, 2025, 03:01 PM
Kalaris Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 47.75%
📈 PositiveBenzinga•Sep 3, 2025, 03:00 PM
Kalaris Reports Loss Cash at 88 Million
📉 NegativeThe Motley Fool•Aug 13, 2025, 12:22 PM
Frequently Asked Questions about KLRS
What is KLRS's current stock price?
Kalaris Therapeutics Inc (KLRS) is currently trading at $9.13 per share. The stock has moved -12.38% today.
What is the analyst price target for KLRS?
The average analyst price target for KLRS is $3.00, based on 1 analyst.
What sector is Kalaris Therapeutics Inc in?
Kalaris Therapeutics Inc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KLRS's market cap?
Kalaris Therapeutics Inc has a market capitalization of $0.17 billion, making it a small-cap company.
Does KLRS pay dividends?
No, Kalaris Therapeutics Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
Explore stocks similar to KLRS for comparison